Early detection of cognitive decline in mild cognitive impairment and Alzheimer's disease with a novel eye tracking test

J Neurol Sci. 2021 Aug 15:427:117529. doi: 10.1016/j.jns.2021.117529. Epub 2021 Jun 3.

Abstract

Due to an increasing number of dementia patients, the development of a rapid and sensitive method for cognitive assessment is awaited. Here, we examined the usefulness of a novel and short (3 min) eye tracking device to evaluate the cognitive function of normal control (NC, n = 52), mild cognitive impairment (MCI, n = 52), and Alzheimer's disease (AD, n = 70) subjects. Eye tracking total score declined significantly in MCI (**p < 0.01 vs NC) and AD (**p < 0.01 vs NC, ##p < 0.01 vs MCI), and correlated well with the mini-mental state examination (MMSE) score (r = 0.57, *p < 0.05). Furthermore, the eye tracking test, especially memory and deductive reasoning tasks, effectively discriminated NC, MCI and AD. The present novel eye tracking test clearly discriminated cognitive functions among NC, MCI, and AD subjects, thereby providing an advantage for the early detection of MCI and AD in screening.

Keywords: Alzheimer’s disease; Cognitive assessment; Eye tracking technology; Mild cognitive impairment.

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Cognitive Dysfunction* / diagnosis
  • Early Diagnosis
  • Eye-Tracking Technology
  • Humans
  • Mass Screening
  • Neuropsychological Tests